US 11,938,125 B2
Use of Hsp70 as a regulator of enzymatic activity
Thomas Kirkegaard Jensen, Rødovre (DK); and Marja H. Jaattela, København Ø (DK)
Assigned to ZEVRA DENMARK A/S, Copenhagen N. (DK)
Filed by Zevra Denmark A/S, Copenhagen N (DK)
Filed on Mar. 7, 2022, as Appl. No. 17/688,189.
Application 15/854,352 is a division of application No. 15/048,483, filed on Feb. 19, 2016, granted, now 9,884,058, issued on Feb. 6, 2018.
Application 15/048,483 is a division of application No. 13/969,944, filed on Aug. 19, 2013, granted, now 9,289,472, issued on Mar. 22, 2016.
Application 17/688,189 is a continuation of application No. 16/698,277, filed on Nov. 27, 2019, granted, now 11,304,941.
Application 16/698,277 is a continuation of application No. 15/854,352, filed on Dec. 26, 2017, granted, now 10,543,204, issued on Jan. 28, 2020.
Application 13/969,944 is a continuation of application No. 13/001,316, granted, now 8,540,985, issued on Sep. 24, 2013, previously published as PCT/DK2009/050151, filed on Jun. 26, 2009.
Claims priority of application No. PA 2008 00885 (DK), filed on Jun. 26, 2008.
Prior Publication US 2022/0362234 A1, Nov. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4545 (2006.01); A61K 31/445 (2006.01); A61K 31/56 (2006.01); A61K 33/30 (2006.01); A61K 38/16 (2006.01); A61K 38/17 (2006.01); A61K 38/43 (2006.01); A61K 38/46 (2006.01); A61K 38/47 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/4545 (2013.01) [A61K 31/445 (2013.01); A61K 31/56 (2013.01); A61K 33/30 (2013.01); A61K 38/16 (2013.01); A61K 38/17 (2013.01); A61K 38/1709 (2013.01); A61K 38/43 (2013.01); A61K 38/46 (2013.01); A61K 38/47 (2013.01); A61K 45/06 (2013.01); C12Y 306/01003 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A method for treating Gaucher disease in a human comprising orally administering arimoclomol citrate or arimoclomol maleate, or a pharmaceutically acceptable salt thereof, to a human.